par Casneuf, Veerle F;Delrue, Louke;Van Damme, Nancy;Demetter, Pieter 
;Robert, Philippe;Corot, Claire;Duyck, Philippe;Ceelen, Wim;Boterberg, Tom;Peeters, Marc
Référence Radiation research, 175, 1, page (10-20)
Publication Publié, 2011-01
;Robert, Philippe;Corot, Claire;Duyck, Philippe;Ceelen, Wim;Boterberg, Tom;Peeters, MarcRéférence Radiation research, 175, 1, page (10-20)
Publication Publié, 2011-01
Article révisé par les pairs
| Résumé : | A predictive technique in the management of patients with cancer could improve the therapeutic index by allowing better individualization of treatment. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive technique that can provide anatomical and physiological information on the tumor and its microenvironment. We studied the effect of chemotherapy (gemcitabine), anti-angiogenesis therapy (sunitinib) and radiotherapy on the kinetics of DCE-MRI parameters in a preclinical model of pancreatic cancer using P846, a new low-diffusible contrast agent. Mice underwent DCE-MRI before treatment (MRI1), after 1 week of treatment (MRI2), and after 1 additional week (MRI3). Combined treatment with radiotherapy and sunitinib had a synergistic effect on tumor growth. In radiotherapy/sunitinib-treated mice, a decrease in K(trans) at MRI2 predicted its superior antivascular and antitumor effect at an early time. An increased K(trans) at MRI2, as seen in gemcitabine- and gemcitabine/sunitinib-treated mice, reflects increased permeability for P846 and might predict a smaller therapeutic effect at this early time. This study shows that the kinetics of DCE-MRI parameters depends on the contrast agent used. P846 appears to be a promising low-diffusible agent to monitor therapeutic effects in this preclinical cancer model, but further studies are needed to compare its behavior with Gd-DTPA and macromolecular-weight contrast agents. Sunitinib as a radiosensitizer is promising for future clinical trials in human pancreatic cancer. |
